Protein Summary
Involved in regulation of intracellular signaling pathways during development. Specifically thought to play a role in canonical and/or non-canonical Wnt signaling pathways through interaction with DSH (Dishevelled) family proteins. The activation/inhibition of Wnt signaling may depend on the phosphorylation status. Proposed to regulate the degradation of CTNNB1/beta-catenin, thereby modulating the transcriptional activation of target genes of the Wnt signaling pathway. Its function in stabilizing CTNNB1 may involve inhibition of GSK3B activity. Promotes the membrane localization of CTNNB1. The cytoplasmic form can induce DVL2 degradation via a lysosome-dependent mechanism; the function is inhibited by PKA-induced binding to 14-3-3 proteins, such as YWHAB. Seems to be involved in morphogenesis at the primitive streak by regulating VANGL2 and DVL2; the function seems to be independent of canonical Wnt signaling and rather involves the non-canonical Wnt/planar cell polarity (PCP) pathway ...more
- ENST00000335867
- ENSP00000337439
- ENSG00000165617
- ENST00000395153
- ENSP00000378582
- DPR1
- HNG3
- DPR1
- TBS2
- FRODO
- HDPR1
- DAPPER
- THYEX3
- DAPPER1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
biological process | 0.93 | ||
PubMedID | 0.79 | ||
histone modification site profile | 0.72 | ||
transcription factor | 0.7 | ||
interacting protein | 0.66 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 449.5 (req: < 5)
Gene RIFs: 34 (req: <= 3)
Antibodies: 139 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 449.5 (req: >= 5)
Gene RIFs: 34 (req: > 3)
Antibodies: 139 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 25
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0